Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- GCP for Medical Devices to Be Amended
March 10, 2008
- TOPICS／Dr Karasawa Will Soon Be Back to Office: JMA
March 10, 2008
- Teijin's Gout Treatment TMX-67 Receives Approvable Letter in the EU
March 10, 2008
- Nippon Shinyaku Enters the Field of OB-GYN with IKH-01
March 10, 2008
- Kyowa Hakko Receives Not-Approvable Letter from FDA for Istradefylline
March 10, 2008
- Alfresa Directly Enters Kyushu Market
March 10, 2008
- Toledomin's Initial Dose to Be Changed Following Reexamination
March 10, 2008
- Schering-Plough Expands Its Pipeline by Acquisition of Organon
March 10, 2008
- Moves to Use iPS Cells for Drug Discovery Precipitated
March 10, 2008
- NEW PRODUCTS／Imigran Self-injection Kit for Headaches: GSK
March 10, 2008
- R&D NEWS IN BRIEF
March 10, 2008
- HUMIRA, Irbesartan Recommended for Approval
March 10, 2008
- NEW PRODUCTS／Shionogi: Allerport TARC
March 10, 2008
- Sutent, Famvir Recommended for Approval
March 10, 2008
- New Data Reinforce Superiority of EVAR in AAA Repair: Cook Medical
March 10, 2008
- Chugai Applies for Capecitabine + Bevacizumab + Oxaliplatin Regimen
March 10, 2008
- MEDICAL DEVICE NEWS IN BRIEF
March 10, 2008
- Takeda Applies for Ramelteon for the Treatment of Insomnia
March 10, 2008
- Reward Good DPC Hospitals by Introducing Japanese Version of P4P: Prof. Muto
March 10, 2008
- Acute-Stage Indications for Piroxicam Deleted: Korosho
March 10, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…